Volume 2, Number 1 January/February 1999
This issue contains the scientific abstracts of ISPOR Inaugural European Conference (click here to view the list and authors of the abstracts).
Volume 2, Number 2 March/April 1999
PROCEEDINGS OF THE ADVISORY PANEL MEETING AND CONFERENCE ON PHARMACOECONOMIC ISSUES
Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary
Jean Paul Gagnon, PhD, Marilyn Dix Smith, PhD, Donna Rindress, PhD
Panel 1: Methodological Issues in Pharmacoeconomic Evaluations-Clinical Studies
Margaret Healey, PhD, Patricia Deverka, MD, MS
Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations-Modeling Studies
Joel Hay, PhD, Joseph Jackson, PhD
Panel 3: Methodological Issues in Conducting Pharmacoeconomic Evaluations-Retrospective and Claims Database Studies
Renee Goldberg Arnold, PharmD, James G. Kotsanos, MD, MS
Panel 4: Education and Skills Needed to Conduct, Interpret, and Use Economic Evaluations in Healthcare
Katie Copley-Merriman, MS, MBA, Gordon Vanscoy, PharmD, MBA
Panel 5: Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making
Jon Clouse, RPh, MS, Jean Paul Gagnon, PhD
Panel 6: Addressing Questions of Bias, Credibility, and Quality in Health Economic Evaluations
Rod Barnes, MBA, Alan Heaton, PharmD
Panel 7: Communication and Reporting Health Economic Information
Alan Bakst, RPh, MS, PharmD, Elaine Power, MPP
ORIGINAL ARTICLE
Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion
Nancy K. Leidy, PhD, Dennis A. Revicki, PhD, Bernard Genesté
Volume 2, Number 3 May/June 1999
This issue contains the scientific abstracts of ISPOR Fourth Annual International Meeting ( please go to Fourth Annual International Meeting page and click on the schedule for each day of the meeting to view the list of abstracts and their authors ).
ORIGINAL ARTICLE
Pharmacoeconomic Perspective in Russia
L.S. Stratchounski, MD, PhD and O.L. Rozenson, MD
Volume 2, Number 4 July/August 1999
(click on article title to view abstract)
EDITORIAL
Comparing the quality of care provided by health plans: are the data there?
R. Adams Dudley, MD, MBA
ORIGINAL ARTICLES
Assessment of Quality of Care for Managed Care and Fee-For-Service Patients Based on Analysis of Avoidable Hospitalizations
L. Clark Paramore, MSPH, Anne Elixhauser, PhD
The Role of SSRI Antidepressants for Treating Depressed Patients in the California Medicaid (Medi-Cal) Program
Jeffrey S McCombs, PhD, Michael B Nichol, PhD, Glen L Stimmel, PharmD
Towards a European Consensus on Conducting and Reporting Health Economic Evaluations—A Report from the ISPOR Inaugural European Conference
Mireille M. Goetghebeur, PhD, Donna Rindress, PhD
Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement
David Bergqvist, MD, PhD, Bengt Jönsson, PhD
Postmarketing Studies: Benefits and Risks
Frances B. Garfield, PhD, J. Jaime Caro, MDCM
An Analysis of the Impact of Demographic, Clinical, and Social Factors on Health-Related Quality of Life
George J Wan, PhD, MPH, Michael A Counte, PhD, David F Cella, PhD, Lesbia Hernandez, PharmD, MPH, Shirley Deasy, MA, Gail Shiomoto, MD
Volume 2, Number 5 September/October 1999
This issue contains the scientific abstracts of ISPOR Second Annual European Conference (please go to Second Annual European Conference page and click on the schedule for each day of the meeting to view the list of abstracts and their authors)
(click on article title to view abstract)
EDITORIAL
Pharmacoeconomics in European Decision-Making
M.J.C. Nuijten, MD, MBA
ORIGINAL ARTICLES
Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe
Michael Drummond, BSc, MCom, DPhil, Dominique Dubois, MD, FFPM, Livio Garattini, PhD, Bruno Horisberger, MD, Bengt Jönsson, Ivar Sönbö Kristiansen, MD, PhD, MPH, Claude Le Pen, PhD, Carlos Gouveia Pinto, PhD, Peter Bo Poulsen, PhD, MSc, Joan Rovira, PhD, Frans Rutten, PhD, Matthias Graf von der Schulenburg, PhD, Harri Sintonen, PhD
The Influence of Case Mix, Site Selection, and Methods Biases on Costs of Hospitalization for Acute Exacerbations of Chronic Obstructive Airways Disease and Lower Respiratory Tract Infections
Peter G. Davey, MD, Alex D. McMahon, BSc, Debra Irwin, MSPH, PhD, Pippa Anderson, BSc, MSc, Andrew M. Morris, MD, Thomas M. MacDonald, MD
Norwegian Version of the Psoriasis Disability Index - A Validation and Reliability Study
A.K. Wahl, stud.Dr.polit, I. Wicklund, PhD, T. Moum, Dr.polit, B.R. Hanestad, Dr.poli
Volume 2, Number 6 November/December 1999
EDITORIAL
Health Care Costs and Outcomes: How Should We Evaluate Real World Data?
Joel Hay, PhD
METHODS
Stochastic Cost-Effectiveness Analysis: A Simultaneous Marginal-Effect Approach
Gordon Liu, PhD, Zhongyun Zhao, PhD
Estimating Endogenous Treatment Effects in Retrospective Data Analysis
Joseph Terza, PhD
EMPIRICAL FINDINGS
Controlling for Systematic Selection in Retrospective Analyses: An Application to Fluoxetine and Sertraline Prescribing in the United Kingdom
Cheryl A Neslusan, PhD, Timothy R Hylan, PhD, Rodney L Dunn, MS, John Donoghue, BS, MRPharmS
Noncompliance with Drug Therapy for Chronic Obstructive Pulmonary Disease: A Risk Factor for Hospitalization?
Karl Matuszewski, MS, PharmD, Palangat Velayudhan, MA, MS, Nora Flint, PharmD, Paul Pierpaoli, MS
Incontinence Drug Utilization Patterns in Québec, Canada
Alain Desgagné, MSc, Jacques LeLorier, MD, PhD, FRCPC
Volume 1, Number 1 May/June 1998
This issue contains the scientific abstracts of ISPOR Third Annual International
Meeting featuring over 200 contributed research and invited presentations.
Volume 1, Number 2 July/August 1998
(click on article title to view abstract)
Atherosclerosis, Acute Coronary Events, and Cholesterol-Lowering: A New Paradigm
Daniel J. Rader MD, University of Pennsylvania
Lipoproteins and Cardiovascular Disease: Biological Basis and
Epidemiological Studies
William Castelli MD, Framingham Cardiovascular Institute
Landmark Trials in Lipid Reduction
W. Virgil Brown MD, Emory University
Conference Round Table: Cholesterol and Heart Disease: Is LDL Reduction the Only Focus?
Prevention of Heart Disease: Is LDL Reduction the Outcome of
Choice? ABSOLUTELY YES
Evan A. Stein MD, PhD
Prevention of Heart Disease: Is LDL Reduction the Outcome of Choice?: NO, THERE IS MORE
Jim Shepherd MD and J.S. Park, PhD
Cardiovascular Disease and Lipoproteins: Available Evidence and Remaining Questions, Reactor Panel and Open Forum
J. Sanford Schwarz, MD; W. Virgil Brown, MD; Mark Hlatky, MD; and William Castelli, MD
Volume 1, Number 3 September/October 1998
(click on article title to view abstract)
PROCEEDINGS OF THE ISPOR LIPID CONFERENCE:
Pharmacoeconomics and Outcomes Research Issues of Lipid Therapy, The Second General Session: Pharmacoeconomics and Outcomes Controversies in Lipid Therapy
The Economics of Hypercholesterolemia and Lipid-Lowering Therapy: A Brief Historical Tour
Gerry Oster PhD
Lipid-Lowering Pharmacoeconomic Studies Reactor Panel and Open Forum
William F. McGhan PharmD, PhD; Alistair McGuire PhD; Talat Ashraf MD; and J. Sanford Schwartz PhD
Conference Round Table: Methodology Issues in Lipid Pharmacoeconomic Investigations
Compliance and the Real World
Susan Andrade ScD
Use of Surrogate Measures and Efficiency Frontier Analysis
Thomas Delea, MSIA
Clinical Trials and External Validity
Bruce Kinosian MD and Henry Glick
Pharmacoeconomic Modeling & Sensitivity Analysis
Joel W. Hay PhD
Methodology Issues in Lipid Pharmacoeconomic Investigations Reactor Panel and Open Forum
J. Sanford Schwartz MD; Alistair McGuire PhD; Talat Ashraf MD; and Nicolaas Otten PharmD
Volume 1, Number 4 November/December 1998
(click on article title to view abstract)
PROCEEDINGS OF THE ISPOR LIPID CONFERENCE:
Pharmacoeconomics and Outcomes Research Issues of Lipid Therapy, The Third General Session: Translation from Research into Practice: How Should Healthcare Organizations/Governments Decide About Lipid Therapy and Who Will Pay?
Making Decisions at the Patient Level on Lipid Therapy
What is Happening in the Real World in Lipid Therapy and Is It Appropriate? The Need for a Paradigm Shift
Sidney C. Smith, Jr. MD
Criteria for the Economic Evaluation of Lipid Studies in Health Systems
Paul C. Langley PhD
Patient Education and Compliance: How to Make it Cost-Effective
James M. McKenney PharmD
Commentary on Langley and McKenney Papers
Talat Ashraf MD; Paul C. Langley PhD; Joel W. Hay PhD; James Bonnette MD; James M. McKenney PharmD
From Research into Practice: How Should Healthcare Organizations/Governments Decide About Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum
Paul C. Langley PhD; Joel W. Hay PhD; J. Sanford Schwartz MD; Sidney C. Smith MD; and james McKenney PharmD
ORIGINAL ARTICLE
Prevalence-Based Economic Evaluation
Josephine Mauskopf PhD
Value In
Health index
|
